Morristown Medical Center’s Gagnon Cardiovascular Institute is first in the U.S. to perform a leaflet modification procedure with ShortCut
Solution Designed to Reduce the Risk of Coronary Obstruction During TAVR
MORRISTOWN, NJ (Morris County) – On February 25, Philippe Généreux, M.D. and Gennaro Giustino, M.D. and their team successfully performed a procedure using ShortCut™, the world’s first FDA cleared device that is dedicated to leaflet modification, enabling a safer valve-in-valve (ViV) Transcatheter Aortic Valve Replacement (TAVR) procedure in patients at risk of coronary obstruction.
This is the first time this device was used commercially in the United States.
TAVR has become the preferred treatment for aortic stenosis, recently surpassing surgery even in patients younger than 65.* As bioprosthetic valves degenerate over time, these patients will at some point likely need a valve-in-valve procedure to be performed, and a significant portion of them who are at risk for coronary obstruction will require leaflet splitting with ShortCut™.
Recently published models predict that by 2035, more than 40,000 valve-in-valve (ViV) procedures will be performed annually in the U.S., representing more than 15% of all TAVR procedures.**
“We are honored to have performed the first commercial ShortCut™ procedure and to be at the forefront of the innovative field of leaflet modification,” said Dr. Généreux, Medical Director of the Structural Heart Program at Morristown Medical Center’s Gagnon Cardiovascular Institute. “In the past, treating this challenging patient population was possible with surgical approaches or complex techniques. With ShortCut™, we safely split both the RCC and LCC leaflets in a simple, predictable, and controlled manner, enabling safe placement of a TAVR.”
Morristown Medical Center has the largest TAVR program in New Jersey and is the top program in the nation. Earlier this year, its structural heart program marked a significant milestone of performing over 5,000 TAVR procedures, the first in New Jersey and among the first to accomplish this in the United States.
Future planned indication expansion into native and bicuspid valves may mean that around 30% of future TAVR cases will require leaflet modification with ShortCut™ in order to be performed safely and obtain optimal results for patients.
ShortCut is a ground-breaking device that is specifically designed to mechanically split preexisting valve leaflets prior to TAVR, aiming to reduce the risk of coronary obstruction or impaired coronary access and enabling a safer ViV TAVR procedure. For more information, visit https://www.pi-cardia.net/
